Table 3 Clinico-pathological data of 1009 patients with “Triple Negative” breast cancer based on histologic subtypes. Sardinia, Italy 1994–2015
IBC-NST (n = 744) n (%) | Lobular (n = 62) n (%) | Apocrine (n = 43) n (%) | Adenoid cystic (n = 6) n (%) | Metaplastic (n = 46) (%) | Medullary (n = 39) n (%) | Other (n = 27) n (%) | p value* | |
|---|---|---|---|---|---|---|---|---|
Site | ||||||||
Right | 328 (49.1) | 23 (52.2) | 15 (44.1) | 3 (50.0) | 16 (38.1) | 17 (48.6) | 12 (50.0) | 0.977 |
Left | 334 (50.0) | 21 (47.7) | 19 (55.9) | 3 (50.0) | 26 (61.9) | 18 (51.4) | 12 (50.0) | |
Bilateral | 6 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Missing | 76 | 18 | 9 | 4 | 4 | 3 | ||
Histologic grade | ||||||||
G1 | 5 (0.7) | 1 (2.0) | 2 (4.7) | 2 (33.3) | 0 (0.0) | 1 (2.7) | 1 (4.0) | < 0.001 |
G2 | 128 (17.8) | 25 (50.0) | 18 (41.9) | 3 (50.0) | 4 (8.9) | 3 (8.1) | 8 (32.0) | |
G3 | 588 (81.6) | 24 (48.0) | 23 (53.5) | 1 (16.7) | 41 (91.1) | 33 (89.2) | 16 (64.0) | |
Missing | 23 | 12 | 1 | 2 | 2 | |||
Tumor size | ||||||||
pT0 | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0.) | 0 (0.0) | 0 (0.0) | 0.110 |
pT1 | 285 (39.7) | 14 (24.6) | 22 (51.2) | 5 (83.3) | 13 (28.3) | 17 (44.7) | 8 (32.0) | |
pT2 | 337 (47.0) | 32 (56.1) | 17 (39.5) | 1 (16.7) | 22 (47.8) | 17 (44.7) | 9 (36.0) | |
pT3 | 32 (4.5) | 7 (12.3) | 3 (7.0) | 0 (0.0) | 9 (19.6) | 3 (7.9) | 4 (16.0) | |
pT4 | 43 (6.0) | 2 (3.5) | 1 (2.3) | 0 (0.0) | 2 (4.3) | 1 (2.6) | 3 (12.0) | |
pTx | 18 (2.5) | 2 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.0) | |
Tis | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Missing | 27 | 5 | 1 | 2 | ||||
Lymph node status | ||||||||
pN0 | 395 (56.3) | 22 (38.6) | 28 (65.1) | 3 (60.0) | 30 (65.2) | 24 (63.2) | 10 (40.0) | 0.190 |
pN1 | 155 (22.1) | 15 (26.3) | 7 (16.3) | 2 (40.0) | 11 (23.9) | 11 (28.9) | 11 (44.0) | |
pN2 | 68 (9.7) | 9 (15.8) | 5 (11.6) | 0 (0.0) | 4 (8.7) | 1 (2.6) | 2 (8.0) | |
pN3 | 47 (6.7) | 7 (12.3) | 3 (7.0) | 0 (0.0) | 0 (0.0) | 1 (2.6) | 1 (4.0) | |
pNx | 36 (5.1) | 4 (7.0) | 0 (0.0) | 0 (0.0) | 1 (2.2) | 1 (2.6) | 1 (4.0) | |
Missing | 43 | 5 | 1 | 1 | 2 | |||
Metastasis | ||||||||
M0 | 649 (87.2) | 55 (88.7) | 41 (95.3) | 5 (83.3) | 41 (89.1) | 38 (97.4) | 21 (77.8) | 0.190 |
M1 | 95 (12.8) | 7 (11.3) | 2 (4.7) | 1 (16.7) | 5 (10.9) | 1 (2.6) | 6 (22.2) | |
TNM stage | ||||||||
I | 188 (28.5) | 8 (15.1) | 19 (44.2) | 3 (50.0) | 10 (22.2) | 11 (29.7) | 5 (21.7) | 0.210 |
II | 306 (46.4) | 27 (50.9) | 15 (34.9) | 2 (33.3) | 24 (53.3) | 23 (62.2) | 10 (43.5) | |
III | 137 (20.8) | 15 (28.3) | 9 (20.9) | 1 (16.7) | 9 (20.0) | 2 (5.4) | 7 (30.4) | |
IV | 28 (4.2) | 3 (5.7) | 0 (0.0) | 0 (0.0) | 2 (4.4) | 1 (2.7) | 1 (4.3) | |
Missing | 85 | 9 | 1 | 2 | 4 | |||
Lympho node ratio | ||||||||
< 0.2 | 520 (81.0) | 35 (64.8) | 36 (85.7) | 5 (100.0) | 38 (86.4) | 32 (91.4) | 19 (82.6) | 0.019 |
0.21–0.65 | 75 (11.7) | 8 (14.8) | 4 (9.5) | 0 (0.0) | 5 (11.4) | 3 (8.6) | 4 (17.4) | |
> 0.65 | 47 (7.3) | 11 (20.4) | 2 (4.8) | 0 (0.0) | 1 (2.3) | 0 (0.0) | 0 (0.0) | |
Missing | 102 | 8 | 1 | 1 | 2 | 4 | 4 | |
Proliferation index (Ki-67) | ||||||||
< 14% | 54 (7.6) | 20 (37.0) | 7 (16.3) | 2 (33.3) | 2 (4.4) | 2 (5.3) | 3 (11.1) | < 0.001 |
15–30% | 110 (15.6) | 11 (20.4) | 13 (30.2) | 1 (16.7) | 5 (11.1) | 2 (5.3) | 8 (29.6) | |
≥ 30% | 542 (76.8) | 23 (42.6) | 23 (53.5) | 3 (50.0) | 38 (84.4) | 34 (89.5) | 16 (59.3) | |
Missing | 38 | 8 | 1 | 1 | ||||
In situ component | ||||||||
Present | 112 (15.1) | 2 (3.2) | 8 (18.6) | 0 (0.0) | 3 (6.5) | 2 (5.1) | 4 (14.8) | 0.038 |
Absent | 632 (84.9) | 60 (96.8) | 35 (81.4) | 6 (100.0) | 43 (93.5) | 37 (94.9) | 23 (85.2) | |
Lymphovascular invasion | ||||||||
yes | 276 (46.0) | 16 (51.6) | 18 (50.0) | 2 (33.3) | 18 (42.9) | 2 (7.4) | 12 (60.0) | 0.004 |
no | 324 (54.0) | 15 (48.4) | 18 (50.0) | 4 (66.7) | 24 (57.1) | 25 (92.6) | 8 (40.0) | |
Missing | 144 | 31 | 7 | 4 | 12 | 7 | ||
Necrosis | ||||||||
Present | 388 (62.7) | 13 (37.1) | 15 (39.5) | 0 (0.0) | 36 (83.7) | 13 (50.0) | 12 (60.0) | < 0.001 |
Absent | 231 (37.3) | 22 (62.9) | 23 (60.5) | 6 (100.0) | 7 (16.3) | 13 (50.0) | 8 (40.0) | |
Missing | 125 | 27 | 5 | 3 | 13 | 7 | ||
Lymphocytic infiltrate | ||||||||
yes | 397 (65.2) | 11 (36.7) | 27 (75.0) | 0 (0.0) | 24 (60.0) | 24 (92.3) | 13 (65.0) | < 0.001 |
no | 212 (34.8) | 19 (63.3) | 9 (25.0) | 6 (100.0) | 16 (40.0) | 2 (7.7) | 7 (35.0) | |
Missing | 135 | 32 | 7 | 6 | 13 | 7 | ||
Androgen receptor | ||||||||
Positive | 79 (19.6) | 10 (76.9) | 24 (88.9) | 0 (0.0) | 3 (9.7) | 1 (6.3) | 4 (33.3) | < 0.001 |
Negative | 324 (80.4) | 3 (23.1) | 3 (11.1) | 4 (100.0) | 28 (90.3) | 15 (93.8) | 8 (66.7) | |
Missing | 341 | 49 | 16 | 2 | 15 | 23 | 15 | |
Type of surgery | ||||||||
Mastectomy | 244 (40.7) | 23 (53.5) | 19 (51.4) | 0 (0.0) | 19 (59.4) | 12 (35.3) | 12 (50.0) | 0.369 |
Quadrantectomy | 342 (57.0) | 20 (46.5) | 18 (48.6) | 4 (100.0) | 21 (65.6) | 22 (64.7) | 11 (45.8) | |
Lumpectomy | 14 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.3) | 0 (0.0) | 1 (4.2) | |
Missing | 144 | 19 | 6 | 2 | 4 | 5 | 3 | |
Adjuvant chemotherapy | ||||||||
yes | 436 (58.6) | 34 (54.8) | 25 (58.1) | 2 (33.3) | 29 (63.0) | 22 (56.4) | 19 (70.4) | 0.685 |
no | 308 (41.4) | 28 (45.2) | 18 (41.9) | 4 (66.7) | 17 (37.0) | 17 (43.6) | 8 (29.6) | |
Adjuvant radiotherapy | ||||||||
yes | 258 (34.7) | 17 (27.4) | 20 (46.5) | 1 (16.7) | 19 (41.3) | 14 (35.9) | 12 (44.4) | < 0.001 |
no | 468 (65.3) | 45 (72.6) | 23 (53.5) | 5 (83.3) | 27 (58.7) | 25 (64.1) | 15 (55.6) | |